Nasdaq · CIK 0001645460
CUE Cue Biopharma, Inc.
Insider trading from SEC Form 4. Last filing Jun 6, 2025. Close $27.66 on Oct 9, 2026, +421% from the 52-week low and -27% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
CUEOct 9, 2026 · close 27.66
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cue Biopharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Daniel R Passeri CHIEF EXECUTIVE OFFICER buy | $31k 30,000 shares | +22% | - |
Transactions
The last 15 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | Jill Marie Broadfoot director | AGrant or award Stock Option (right to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | Jun 6, 2025 |
| Mar 21, 2025 | Daniel G. Baker CHIEF DEVELOPMENT OFFICER | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Mar 25, 2025 |
| Mar 21, 2025 | Matteo Levisetti Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Mar 25, 2025 |
| Mar 21, 2025 | Lucinda Warren CHIEF BUSINESS OFFICER | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Mar 25, 2025 |
| Mar 21, 2025 | Colin Sandercock SVP, GENERAL COUNSEL | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Mar 25, 2025 |
| Mar 21, 2025 | Daniel R Passeri CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (right to buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Mar 25, 2025 |
| Mar 21, 2025 | Kerri-Ann Millar CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Mar 25, 2025 |
| Mar 10, 2025 | Pasha Sarraf director | AGrant or award Stock Option (right to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | Mar 12, 2025 |
| Jan 2, 2025 | Pamela Garzone director | AGrant or award Stock Option (right to buy)derivative | +24,400 | $0.00 | $0 | 24,400 | Jan 3, 2025 |
| Jan 2, 2025 | Patrick Verheyen director | AGrant or award Stock Option (right to buy)derivative | +24,400 | $0.00 | $0 | 24,400 | Jan 3, 2025 |
| Jan 2, 2025 | Peter A Kiener director | AGrant or award Stock Option (right to buy)derivative | +24,400 | $0.00 | $0 | 24,400 | Jan 3, 2025 |
| Jan 2, 2025 | Frederick W Driscoll director | AGrant or award Stock Option (right to buy)derivative | +24,400 | $0.00 | $0 | 24,400 | Jan 3, 2025 |
| Jan 2, 2025 | Frank Morich director | AGrant or award Stock Option (right to buy)derivative | +24,400 | $0.00 | $0 | 24,400 | Jan 3, 2025 |
| Dec 16, 2024 | Daniel R Passeri CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +30,000 | $1.03 | $31k | 164,578 | Dec 18, 2024 |
| Nov 25, 2024 | Daniel G. Baker CHIEF DEVELOPMENT OFFICER | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Nov 29, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Daniel G. BakerCHIEF DEVELOPMENT OFFICER
- Jill Marie Broadfootcfo, officer, director
- Frederick W Driscolldirector
- Pamela Garzonedirector
- Peter A Kienerdirector
- Matteo LevisettiChief Medical Officer
- Kerri-Ann MillarCHIEF FINANCIAL OFFICER
- Frank Morichdirector
- Daniel R PasseriCHIEF EXECUTIVE OFFICER
- Colin SandercockSVP, GENERAL COUNSEL
- Pasha Sarrafdirector
- Patrick Verheyendirector
- Lucinda WarrenCHIEF BUSINESS OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.